Adma Biologics(NASDAQ) ADMA

ADMA Biologics, Inc. helps patients with weak immune systems. These treatments protect people from serious infections and Hepatitis B. The company gathers plasma and turns it into products in labs.

Plasma and Protective Products

• ASCENIV: Intravenous immune globulin product for primary immunodeficiency that uses high-titer plasma for specialized protection.
• BIVIGAM: Standard intravenous immune globulin treatment for adults and children with primary humoral immunodeficiency.
• Nabi-HB: Hyperimmune globulin used for the treatment of acute exposure to the Hepatitis B virus; historically represents less than 10% of revenue.
• Plasma Collection Facilities: Locations gathering source plasma for manufacturing and third-party sales; generated $1.4 million in revenue for the six months ended June 30, 2026.

Steps Toward Scaling Up

• Approved a yield enhancement production process in April 2025 to increase bulk drug volume from raw plasma by 20% or more.
• Purchased real estate in Boca Raton, Florida, for $12.6 million in July 2025 to expand production and cold-chain storage.
• Completed the sale of three plasma collection centers in the first quarter of 2026 for $12.0 million to improve capital efficiency.
• Entered a $300 million senior secured credit facility on Aug. 5, 2025, to support corporate growth and strategic initiatives.

What Makes ADMA Different

The Boca Facility provides end-to-end manufacturing with a peak annual processing capacity of 600,000 liters. A proprietary donor screening methodology identifies high-titer plasma for specialized products, which is found in less than 10% of tested samples.

Key Performance Metrics

• Total revenues reached $238.9 million for the six months ended June 30, 2026, a 0.9% increase from the prior year.
• ASCENIV revenue rose 25.5% to $200.4 million during the six-month period ended June 30, 2026.
• Net income rose to $83.2 million for the six-month period ended June 30, 2026, compared to $61.1 million in 2025.
• Gross margin improved to 69.9% for the first half of 2026, up from 54.2% in the first half of 2025.
• Cash and cash equivalents totaled $136.0 million as of June 30, 2026, following the receipt of proceeds from plasma center sales.

Bottom Line

ADMA has transitioned from a development-stage firm to a profitable biopharmaceutical manufacturer with a focus on high-margin specialty products. Its shift toward a capital-efficient supply model and manufacturing enhancements supports its long-term commercial operations.